Working with Healthcare Professionals

Our approach

Boehringer Ingelheim has sought to develop innovative new medicines for well over 130 years, in a quest to improve the health and wellbeing of society. These new medicines are the result of decades of research, development and clinical testing. Healthcare professionals play a pivotal role along this development process. As new medicines come to market, with the potential to significantly benefit the health and welfare of Australian patients, Boehringer Ingelheim engages in the education of healthcare professionals in Australia to ensure the safe, effective and appropriate use of our medicines.

We also work with healthcare professionals to improve patient care, build shared knowledge and identify future patient needs that can be met through our research and development. This dialogue is critical to ensure that the needs of Australian patients are being best met. We believe that this interaction with healthcare professionals benefits patient care, and enables advances to be made in the therapeutic areas in which the company operates.

We also believe that healthcare professionals who provide independent advice or offer their expertise to develop or deliver appropriate education to relevant audiences should be fairly compensated for their time, services and expertise. Boehringer Ingelheim has for many years supported extensive medical education of Australian healthcare professionals with the aim of improving patient care. Through educational programs accredited by Australian institutions, peer-led meetings, and support of independent scientific meetings, Boehringer Ingelheim is strongly committed to the advancement of patient care.

All of our interactions with Australian healthcare professionals are highly professional, ethical and strictly adhere not only to the company’s high ethical standards, but also to the standards set out in the Medicines Australia Code of Conduct. We fully understand that the community needs to have confidence in these interactions. The pharmaceutical industry, through Medicines Australia has been a leader in the Australian healthcare sector in developing and implementing a robust Code of Conduct that governs these relationships to ensure they are ethical and transparent.

Boehringer Ingelheim is committed to listening and evolving to meet community expectations on how we work with healthcare professionals, while providing important medicines that prevent and treat diseases in Australian patients and ensuring quality education both in regard to therapeutic areas and appropriate use of medicines within these areas.

The Transfer of Value Report – Boehringer Ingelheim Australia

This report highlights the significant value Boehringer Ingelheim delivers to Australia’s healthcare system through the support of professional training and medical education for healthcare professionals. This is particularly important at a time when our state and federal budgets are under increasing pressure.

Boehringer Ingelheim's Transfer of Value Reports

Reporting Period Report File
1 November 2018 to 30 April 2021

This information is now held in a database, administered by Medicines Australia. This database is designed to be searchable as well as downloaded as a CSV file.

For further information about the details in the report, or to search the database, please visit www.DisclosureAustralia.com.au
1 May 2018 to 31 October 2018 Download PDF | Download CSV

About the Report 

As a member of Medicines Australia, Boehringer Ingelheim has undertaken to be open and transparent when we provide a reportable payment or transfer of value to a healthcare professional.

Reportable payments or transfers of value are:

  • Payments for the provision of services such as giving a lecture, chairing an educational meeting, providing advice as a member of an Advisory Board or as a Consultant; and
  • Airfares, accommodation and/or conference registration fees to attend medical education as part of those services.

Boehringer Ingelheim has prepared the report for publication in accordance with the Medicines Australia Code of Conduct, Edition 18 and Australia’s Privacy legislation. The report identifies healthcare professionals by name where their consent has been provided. Where consent has not been provided the information is reported in aggregate.

From 1 October 2016, reporting these payments is mandatory – details will be reported because healthcare professionals should reasonably expect that all reportable payments or transfers of value will be disclosed for each healthcare professional, by name.The report is available for at least three years from the date of publication.

From 30 August 2019, this information is now held in a database, administered by Medicines Australia. This database is designed to be searchable as well as downloaded as a CSV file.

To comply with our privacy obligations, the report may be amended from time to time. The report here contains the most up to date information. Any use or disclosure of the data by a third party is the responsibility of that third party, who must comply with the Australian Privacy Act 1988.

For further information about the details in the report, please go to medicinesaustralia.com.au

Learn more about how we work with Health Consumer Organisations 

Learn more about Clinical Research in Australia